Table 2 Classification of attributes in 24 DCE/CA studies

Amin, S.

Median OS, Median PFS

Risk of neuropathy, Risk of neutropenia, Risk of nausea, Risk of alopecia, Risk of immune-related AE

Fernández, O.

Progression survival gain

Risk of SAE

Mode of administration

Monthly cost (healthcare system)

HRQoL

Stellato, D.

Chance of progression-free over 24 months

Improvement in pain, Chance of hot flashes, Chance of neutropenia, Chance of nausea

Dosing regimen, Monitoring

Le, H.

Chance of 2-year PFS

Risk of atrial fibrillation, Risk of infection, Risk of tumor lysis syndrome, Risk of bleeding, Risk of arthralgia/myalgia/ musculoskeletal pain, Risk of discontinue due to AES

Duration and administration

Beusterien, K.

Chance of 5-Y invasive DFS

Risk of nausea, Risk of diarrhea, Risk of neutropenia, Risk of alopecia

Dosing schedule, Electrocardiogram monitoring

Maculaitis, M. C.

Risk of dose reduction due to AES, Risk of diarrhea, Risk of abdominal (belly) pain, Risk of III/IV neutropenia

Regimen, Dosing schedule, Electrocardiogram monitoring

Hauber, B

Expected survival, Best-case survival, Worst-case survival

Degree of fecal fatigue, Degree of nausea, Risk of febrile neutropenia

van der Valk, M. J. M.

DFS

Degree of fecal incontinence, Degree of urinary dysfunction, Degree of sexual dysfunction

Further therapies

Worry about cancer recurrence

Fifer, S. J.

OS, Remission period

Risk of SE

Mode & frequency of administration

Out of pocket (annual)

Stenehjem, D. D.

OS

Risk of immunotherapy-related SE, Risk of skin toxicity, Risk of gastrointestinal toxicity

Mode of administration

Out of pocket (month)

Stellato, D.

Chance of cancer-free for 21 months, Chance of free of distant metastases for 21 months, Chance of alive for 36 months

Risk of fever (≥ 39℃), Risk of diarrhea (4–6 episodes daily), Risk of thyroid problems with symptoms

Dosing regimen

Difficulties with work and daily activities

Ivanova, J.

OS, PFS, ORR

Risk of hospitalization due to SE

Treatment schedule

Nakayama, M.

Effect to keep disease stable

Degree of SE

Convenience of treatment

QoL

Gonzalez, J. M.

PFS, 3Y-PL

Degree of skin reactions, Degree of fatigue

Mode & frequency of administration

Co-payment (month)

Bröckelmann, P. J.

5Y-OS, 5Y-PFS

Risk of SE requiring treatment, Risk of peripheral neuropathy, Risk of infertility, Risk of permanent pulmonary toxicity

Liu, F. X.

MDT, ORR, PFS, OS

Risk of III/IV SE

Mode of administration, Dosing regimen

Lee, J. Y.

5Y-recurrence rate

Risk of lymphedema, Surgery-related systemic morbidity

Gonzalez, J. M.

PFS

Risk of severe papulopustular rash, Risk of serious hemorrhage, Risk of cardiopulmonary arrest

Landfeldt, E.

OS, PFS

Degree of fatigue, Degree of nausea, Risk of serious infections

Mode & frequency of administration

de Bekker-Grob, E. W.

Effect of cure

Risk of permanent urinary incontinency, Risk of permanent erectile dysfunction, Risk of other permanent side effects

Frequency of PSA testing with a risk of new prostate biopsies

Park, M. H.

PFS

Risk of bone marrow suppression, Risk of hand-foot skin reaction, Risk of gastrointestinal perforation, Risk of bleeding

Mode of administration

Thrumurthy, S. G.

Mortality, Morbidity, Cure rate

QoL

Hospital type, Surgeon’s reputation

Shafey, M.

Median PFS & 5Y-PFS

Degree of SE

Mode & frequency of administration

Health cost (healthcare system)

Muhlbacher, A. C.

Increase in life-span

Degree of SE

Further therapies, Self-medication, Breaks in treatment

Emotional situation, Physical situation, Social situation